Deprescribing Antipsychotics: a Multiple Case Study

Recruiting now

Conditions studied: Psychotic Disorder

In brief

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc. The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments. This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.

Key facts

Study ID

NCT07343193

Run by

University Hospital, Strasbourg, France

People needed

30

Starts

2025-09-09

Expected to finish

2026-09-09

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years)
• Patients with a psychotic or related disorder
• Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

You may not qualify if…

• Patients who have expressed their opposition to participating in the study

Where it is running

• Service de Psychiatrie 1 - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.